儿童异基因移植中白消安联合环磷酰胺与氟达拉滨的清髓性预处理结局比较
该回顾性分析纳入2008至2014年接受移植的1781例儿童,分别比较BuCy与BuFlu在非恶性与恶性疾病中的效果。非恶性病两组总体死亡可比(RR 1.14,P=0.52),BuFlu组窦状隙阻塞综合征、出血性膀胱炎和慢性移植物抗宿主病发生率更低;恶性病两组移植毒性、移植相关死亡、复发和治疗失败无差异,但BuFlu组总体死亡更高(RR 1.4,P=0.008),与复发后生存较差相关(P=0.001)。
要点
- 非恶性病儿童接受BuFlu或BuCy的总体死亡可比(RR 1.14,P=0.52)。
- BuFlu后窦状隙阻塞综合征(P=0.04)、出血性膀胱炎(P=0.04)、慢性GVHD(P=0.02)发生率更低。
- 恶性病儿童BuFlu组总体死亡更高(RR 1.4,P=0.008),与复发后生存较差相关(P=0.001)。
核心结论
- 儿童接受BuFlu与BuCy的结局相似,但恶性病接受BuFlu者可能因不明原因面临复发后生存较短的风险。
研究设计与样本
- 回顾性分析2008至2014年接受异基因造血细胞移植的1781例儿童,比较BuCy与BuFlu,非恶性与恶性疾病人群分别分析。
主要发现
- 非恶性病儿童接受BuFlu或BuCy的总体死亡可比(RR 1.14,P=0.52)。
- BuFlu后窦状隙阻塞综合征(P=0.04)、出血性膀胱炎(P=0.04)、慢性移植物抗宿主病(P=0.02)发生率更低,但因这些并发症频率低,预处理方案的影响无法通过多变量分析评估。
- 恶性病中,造血细胞移植合并症指数评分较高(P<0.001)或供者无关且HLA不合(P=0.004)的儿童更可能接受BuFlu。
- 恶性病中两组移植毒性无差异,移植相关死亡(RR 1.2,P=0.46)、复发(RR 1.2,P=0.15)和治疗失败(RR 1.2,P=0.12)可比。
- BuFlu与更高的总体死亡相关(RR 1.4,P=0.008),归因于复发后生存较差(P=0.001)。
临床怎么用
- 作者认为儿童接受BuFlu与BuCy的结局相似,但恶性病接受BuFlu者可能因不明原因面临复发后生存较短的风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Busulfan combined with cyclophosphamide (BuCy) has long been considered a standard myeloablative conditioning regimen for allogeneic hematopoietic cell transplantation (HCT), including both nonmalignant conditions and myeloid diseases. Substituting fludarabine for cyclophosphamide (BuFlu) to reduce toxicity without an increase in relapse has been increasingly performed in children, but without comparison with BuCy. We retrospectively analyzed 1781 children transplanted from 2008 to 2014 to compare the effectiveness of BuCy with BuFlu. Nonmalignant and malignant disease populations were analyzed separately. Overall mortality was comparable for children with nonmalignant conditions who received BuFlu or BuCy (relative risk [RR], 1.14, P = .52). Lower incidences of sinusoidal obstruction syndrome (P = .04), hemorrhagic cystitis (P = .04), and chronic graft-versus-host disease (P = .02) were observed after BuFlu, but the influence of the conditioning regimen could not be assessed by multivariate analysis because of the low frequency of these complications. Children transplanted for malignancies were more likely to receive BuFlu if they had higher hematopoietic cell transplantation-comorbidity index scores (P < .001) or their donor was unrelated and HLA-mismatched (P = .004). Nevertheless, there were no differences in transplant toxicities and comparable transplant-related mortality (RR, 1.2; P = .46), relapse (RR, 1.2; P = .15), and treatment failure (RR, 1.2; P = .12). BuFlu was associated with higher overall mortality (RR, 1.4; P = .008) related to inferior postrelapse survival (P = .001). Our findings demonstrated that outcomes after BuFlu are similar to those for BuCy for children, but for unclear reasons, those receiving BuFlu for malignancy may be at risk for shorter postrelapse survival.
引用
- Harris AC, Boelens JJ, Ahn KW, et al. Comparison of pediatric allogeneic transplant outcomes using myeloablative busulfan with cyclophosphamide or fludarabine. Blood Adv. 2018. PMID: 29844205. doi:10.1182/bloodadvances.2018016956
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。